Ocular Therapeutix Management
Management criteria checks 1/4
Ocular Therapeutix's CEO is Pravin Dugel, appointed in Apr 2024, has a tenure of 1.08 years. total yearly compensation is $18.65M, comprised of 2.5% salary and 97.5% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €1.33M. The average tenure of the management team and the board of directors is 1.3 years and 5.9 years respectively.
Key information
Pravin Dugel
Chief executive officer
US$18.7m
Total compensation
| CEO salary percentage | 2.49% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.3yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$193m |
| Dec 31 2024 | US$19m | US$465k | -US$194m |
Compensation vs Market: Pravin's total compensation ($USD18.65M) is above average for companies of similar size in the German market ($USD1.31M).
Compensation vs Earnings: Insufficient data to compare Pravin's compensation with company performance.
CEO
Pravin Dugel (60 yo)
Dr. Pravin U. Dugel, M. D. has been Executive Chairman of Ocular Therapeutix, Inc. since February 21, 2024 and also serves as its Chief Executive Officer and President since April 15, 2024. He served as Pr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.1yrs | US$18.65m | 0.13% € 1.3m | |
| Chief Scientific Officer | 1.3yrs | US$6.67m | 0.044% € 462.8k | |
| Chief Development Officer | 2.9yrs | US$6.69m | 0.018% € 190.4k | |
| CFO, COO & Principal Accounting Officer | 7.7yrs | US$1.34m | 0.077% € 817.6k | |
| Chief Technical Officer | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | no data | no data | no data | |
| Vice President of Global Sales & Marketing | no data | no data | no data | |
| Chief Human Resources Officer | 1.3yrs | no data | no data | |
| Chief Commercial Officer | 2.3yrs | no data | no data | |
| Chief Strategy Officer | 1.3yrs | no data | 0.075% € 791.9k | |
| Chief Medical Officer | no data | no data | no data |
Experienced Management: 0OT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.3yrs | US$18.65m | 0.13% € 1.3m | |
| Lead Independent Director | 17.3yrs | US$406.31k | 0.038% € 402.6k | |
| Independent Director | 3.7yrs | US$366.31k | 0.013% € 139.4k | |
| Independent Director | 12.5yrs | US$363.81k | 0.10% € 1.1m | |
| Independent Director | 1.8yrs | US$351.31k | 0.0050% € 53.2k | |
| Independent Director | 6.2yrs | US$363.81k | 0.016% € 169.4k | |
| Independent Director | 5.9yrs | US$351.31k | 0.013% € 139.4k |
Experienced Board: 0OT's board of directors are considered experienced (5.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 04:52 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ocular Therapeutix, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Anita Dushyanth | Berenberg |
| Tazeen Ahmad | BofA Global Research |